Pfizer, fresh to China’s obesity market, looks to Viagra model to compete
Pfizer is entering China's obesity market with a new GLP-1 drug, Ecnoglutide, in partnership with Sciwind Biosciences. The New York-based company secured mainland China licensing rights to the injection for an upfront payment of $495 million, with additional milestone payments possible. CEO Alber…